Please login to the form below

Not currently logged in
Email:
Password:

Debiopharm

This page shows the latest Debiopharm news and features for those working in and with pharma, biotech and healthcare.

Pancreatitis cases stall Novartis hepatitis C trial

Alisporivir was originally developed by Debiopharm of Switzerland and is a cyclophilin inhibitor that is thought to interfere with proteins the hepatitis C virus needs for replication. ... Novartis licensed rights to alisporivir (formerly Deb 025) from

Latest news

  • Novartis pays $440m for preclinical hepatitis C drug

    At the moment its lead candidate is first-in-class cyclophilin inhibitor DEB025 (alisporivir), licensed from Swiss biotech Debiopharm, which works by blocking part of the replication process within the NS5A

  • Merck and Roche team up for hepatitis C studies

    Meanwhile, a range of other new HCV drugs are coming through the pharma industry's pipelines, including Novartis and Debiopharm's DEB025, Boehringer Ingelheim's BI 201335, Bristol-Myers Squibb 's

  • More Eloxatin settlements for sanofi-aventis

    Mayne/Hospira, MN/Par and Actavis have all settled outstanding litigation regarding certain formulations of Eloxatin, currently under licence by S-A and Debiopharm.

  • Sanofi-aventis settles Eloxatin lawsuits

    medicine. S-A, who hold patent rights for the drug along with Swiss-based Debiopharm, did not give any other details regarding the recent settlements, including financial.

  • Novartis gain rights to hepatitis C drug

    The Swiss drugmakers will make an undisclosed upfront payment to Debiopharm Group, an independent biopharmaceuticals company based in Switzerland, with Novartis receiving exclusive worldwide development and marketing rights (excluding Japan).

More from news
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics